ⓘ Bimekizumab

                                     

ⓘ Bimekizumab

Bimekizumab is a monoclonal antibody that is being investigated for ankylosing spondylitis and psoriasis.

This drug is developed by UCB. In 2018, bimekizumab undergoing phase III clinical trials.